Top publications

  • Singh V, Dhar N, Pató J, Kolly GS, Korduláková J, Forbak M, Evans JC, Székely R, Rybniker J, Palčeková Z, Zemanová J, Santi I, Signorino-Gelo F, Rodrigues L, Vocat A, Covarrubias AS, Rengifo MG, Johnsson K, Mowbray S, Buechler J, Delorme V, Brodin P, Knott GW, Aínsa JA, Warner DF, Kéri G, Mikušová K, McKinney JD, Cole ST, Mizrahi V, Hartkoorn RC
    Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria
    MOLECULAR MICROBIOLOGY 103:(1) pp. 13-25. (2017)
  • Booij TH, Klop MJD, Yan K, Szantai-Kis C, Szokol B, Orfi L, van de Water B, Keri G, Price LS
    Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases
    JOURNAL OF BIOMOLECULAR SCREENING 21:(9) pp. 912-922. (2016)
  • Garamvolgyi R, Dobos J, Sipos A, Boros S, Illyes E, Baska F, Kekesi L, Szabadkai I, Szantai-Kis C, Keri G, Orfi L
    Design and synthesis of new imidazo[1,2-a]pyridine and imidazo [1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 108 pp. 623-643. (2015)
  • Sipos A, Pato J, Szekely R, Hartkoorn RC, Kekesi L, Orfi L, Szantai-Kis C, Mikusova K, Svetlikova Z, Kordulakova J, Nagaraja V, Godbole AA, Bush N, Collin F, Maxwell A, Cole ST, Keri G
    Lead selection and characterization of antitubercular compounds using the Nested Chemical Library
    TUBERCULOSIS 95 pp. S200-S206. (2015)
  • Rybniker J, Chen JM, Sala C, Hartkoorn RC, Vocat A, Benjak A, Boy-Rottger S, Zhang M, Szekely R, Greff Z, Orfi L, Szabadkai I, Pato J, Keri G, Cole ST
    Anticytolytic screen identifies inhibitors of Mycobacterial virulence protein secretion
    CELL HOST & MICROBE 16:(4) pp. 538-548. (2014)
  • Pénzes K, Baumann C, Szabadkai I, Orfi L, Kéri G, Ullrich A, Torka R
    Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells
    CANCER BIOLOGY & THERAPY 15:(11) pp. 1571-1582. (2014)
  • Torka R, Pénzes K, Gusenbauer S, Baumann C, Szabadkai I, Őrfi L, Kéri G, Ullrich A
    Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy
    NEOPLASIA 16:(4) pp. 301-318. (2014)
  • Barman SA, Chen F, Su Y, Dimitropoulou C, Wang Y, Catravas JD, Han W, Orfi L, Szantai-Kis C, Keri G, Szabadkai I, Barabutis N, Rafikova O, Rafikov R, Black SM, Jonigk D, Giannis A, Asmis R, Stepp DW, Ramesh G, Fulton DJ
    NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 34:(8) pp. 1704-1715. (2014)
  • Baska F, Szabadkai I, Sipos A, Breza N, Szántai-Kis C, Kékesi L, Garamvölgyi R, Nemes Z, Baska F, Neumann L, Torka R, Ullrich A, Kéri G, Őrfi L
    Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors
    CURRENT MEDICINAL CHEMISTRY 21:(17) pp. 1938-1965. (2014)
  • Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Őrfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Őrfi L, Vántus T, Kéri G
    Discovery and biological evaluation of novel dual EGFR/c-Met inhibitors
    ACS MEDICINAL CHEMISTRY LETTERS 5:(4) pp. 298-303. (2014)
  • Ho HK, Németh G, Ng YR, Pang E, Szántai-Kis C, Zsákai L, Breza N, Greff Z, Horváth Z, Pató J, Szabadkai I, Szokol B, Baska F, Őrfi L, Ullrich A, Kéri G, Chua BT
    Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
    CURRENT MEDICINAL CHEMISTRY 20:(10) pp. 1203-1217. (2013)
  • Nemeth G, Varga Z, Greff Z, Bencze G, Sipos A, Szantai-Kis C, Baska F, Gyuris A, Kelemenics K, Szathmary Z, Minarovits J, Keri G, Orfi L
    Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection.
    CURRENT MEDICINAL CHEMISTRY 18: pp. 342-358. (2011)
  • Borbely G, Szabadkai I, Horvath Z, Marko P, Varga Z, Breza N, Baska F, Vantus T, Huszar M, Geiszt M, Hunyady L, Buday L, Orfi L, Keri G
    Small-Molecule Inhibitors of NADPH Oxidase 4.
    JOURNAL OF MEDICINAL CHEMISTRY 53:(18) pp. 6758-6762. (2010)
  • Petak I, Schwab R, Orfi L, Kopper L, Keri G
    Integrating molecular diagnostics into anticancer drug discovery.
    NATURE REVIEWS DRUG DISCOVERY 9:(7) pp. 523-535. (2010)
  • Kirti Sharma, Christoph Weber, Michaela Bairlein, Zoltán Greff, György Kéri, Jürgen Cox, Jesper V Olsen, Henrik Daub
    Proteomics strategy for quantitative protein interaction profiling in cell extracts.
    NATURE METHODS 6:(10) pp. 741-744. (2009)
  • Hegymegi-Barakonyi B, Eros D, Szantai-Kis C, Breza N, Banhegyi P, Szabo GV, Varkondi E, Petak I, Orfi L, Keri G
    Tyrosine kinase inhibitors – Small molecular weight compounds inhibiting EGFR.
    CURRENT OPINION IN MOLECULAR THERAPEUTICS 10:(3) pp. 308-321. (2009)
  • Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Keri G, Ullrich A
    AXL is a potential target for therapeutic intervention in breast cancer progression.
    CANCER RESEARCH 68:(6) pp. 1905-1915. (2008)
  • Wissing J, Jansch L, Nimtz M, Dieterich G, Hornberger R, Keri G, Wehland J, Daub H
    Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry.
    MOLECULAR & CELLULAR PROTEOMICS 6:(3) pp. 537-547. (2007)
  • Kéri Gy, Orfi L, Eros D, Hegymegi-Barakonyi B, Szántai-Kis Cs, Horváth Z, Wáczek F, Marosfalvy J, Szabadkai I, Pató J, Greff Z, Hafenbradl D, Daub H, Müller G, Klebl B, Ullrich A
    Signal Transduction Therapy with Rationally Designed Kinase Inhibitors.
    CURRENT SIGNAL TRANSDUCTION THERAPY 1:(1) pp. 67-95. (2006)
  • Keri G, Szekelyhidi Z, Banhegyi P, Varga Z, Hegymegi Barakonyi B, Szantai Kis C, Hafenbradl D, Klebl B, Muller G, Ullrich A, Eros D, Horvath Z, Greff Z, Marosfalvi J, Pato J, Szabadkai I, Szilagyi I, Szegedi Z, Varga I, Waczek F, Orfi L
    Drug discovery in the kinase inhibitory field using the Nested Chemical Library (TM) technology.
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES 3:(5) pp. 543-551. (2005)
  • Godl K, Gruss O J, Eickhoff J, Wissing J, Blencke S, Weber M, Degen H, Brehmer D, Orfi L, Horvath Z, Keri G, Muller S, Cotten M, Ullrich A, Daub H
    Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.
    CANCER RESEARCH 65:(15) pp. 6919-6926. (2005)